Trevi Therapeutics (TRVI) announced that it has completed enrollment in its Phase 2a trial for the treatment of RCC and expects to report topline data in the first quarter of 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRVI:
- Trevi Therapeutics provides update on Haduvio’s clinical development program
- Closing Bell Movers: Ultragenyx Pharmaceutical slips 2% on study update
- Trevi Therapeutics Announces Executive Team Changes and Haduvio Progress
- Trevi Therapeutics appoints James Cassella Chief Development Officer
- Trevi Therapeutics’ Haduvio shows cough relief efficacy in Phase 2a trial